Novavax Vaccine Shows 93% Efficacy Against Covid Variants

The Experimental vaccine against covid-19 developed by Novavax Inc. showed great efficacy against coronavirus, including mutated variants, in a large trial.

The vaccine had a 90% effective in preventing symptomatic cases of covid and 100% effective in preventing moderate and severe symptomsthe US biotech firm reported Monday. The vaccine was 93% effective against variants of concern, he said.

Jorge Geffner: “The Delta variable could have a certain level of resistance to vaccines”

The vaccine uses recombinant protein technology, also used in the experimental vaccine developed by Sanofi and GlaxoSmithKline Plc. At more than 90%, the overall efficacy of the vaccine is close to the rates reported for the mRNA vaccines developed by Pfizer Inc.-BioNTech SE and Moderna Inc., and for the Sputnik V vaccine from Russia, which uses vector technology. viral. However, immunologists tend to caution against comparing efficacy results in different trials, as the conditions and methods of evaluation are not the same.

Novavax’s phase 3 trial included nearly 30,000 participants in the United States and Mexico and studied the efficacy of the vaccine against the main variants circulating in the US., as defined by the Centers for Disease Control and Prevention. Only one case of the highly contagious delta strain – which was first identified in India and remains rare in the US – was detected among trial participants, so the efficacy of the vaccine against it is not conclusive .

In results published in March of a trial of 15,000 people in the UK, the vaccine was 90% effective in preventing covid symptoms in all variants and the original version of the virus.

What is known about the Indian and South African variants found in Argentina

The company previously stated that it would not request authorization for the vaccine in the US and Europe until the third quarter of the year.. Novavax indicates that it is on track to reach a manufacturing capacity of 100 million doses per month by the end of the third quarter, and 150 million per month by the end of 2021.

“Novavax is one step closer to addressing the serious and persistent global need for COVID-19 vaccines,” said the pharmaceutical company CEO Stanley C. Erck in a statement. “Novavax continues to work with a sense of urgency to complete our regulatory filings and deliver this vaccine, built on a well understood and proven platform, to a world that still has a great need for vaccines.”

You may also like